TYRA reported Q4 FY2025 results, ending the quarter with cash, cash equivalents and marketable securities of USD 256.0 million and stating this is expected to fund plans through at least 2027. Q4 R&D expenses were USD 28.2 million (+27%), while G&A expenses were USD 8.3 million (+10.1%). Q4 net loss was USD 33.8 million (+32.2%), with interest and other income, net of USD 2.7 million. For FY2025, R&D expenses were USD 102.9 million (+28.5%) and G&A expenses were USD 29.8 million (+23.8%). FY net loss was USD 119.9 million (+38.7%), and interest and other income, net was USD 12.8 million. Business updates centered on TYRA’s “dabogratinib 3x3” strategy to advance oral dabogratinib, an investigational FGFR3-selective inhibitor, in three late-stage-intent Phase 2 programs: SURF303 in low-grade upper tract urothelial carcinoma (first patient dosing anticipated in 2026), SURF302 in FGFR3-altered intermediate-risk non-muscle invasive bladder cancer (initial three-month complete response data expected by end of H1 2026), and BEACH301 in achondroplasia (interim safety sentinel cohort results, including 6-month average height velocity and safety, expected in H2 2026). TYRA said it exited metastatic bladder cancer to focus resources on these three core indications; SURF301 in metastatic urothelial carcinoma is no longer recruiting. The company also announced leadership appointments of a chief operating officer and a chief regulatory officer.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tyra Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202603021605PR_NEWS_USPR_____LA99114) on March 02, 2026, and is solely responsible for the information contained therein.